Safety and Efficacy of a Locally Produced Novel Anti- BCMA Chimeric Antigen Receptor TCell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma

Eyal Lebel; Nathalie Asherie; Shlomit Kfir-Erenfeld; Avni Batia; Sigal Grisariu; Shlomo Elias; Miri Assayag; Tatyana Dubnikov; Nomi Zalcman; Marjorie Pick; Eran Zimran; Yael C. Cohen; Irit Avivi Mazza; Cyrille Cohen; Moshe E. Gatt; Polina Stepensky

Safety and Efficacy of a Locally Produced Novel Anti- BCMA Chimeric Antigen Receptor TCell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma

Eyal Lebel, Nathalie Asherie, Shlomit Kfir-Erenfeld, Avni Batia, Sigal Grisariu, Shlomo Elias, Miri Assayag, Tatyana Dubnikov, Nomi Zalcman, Marjorie Pick, Eran Zimran, Yael C. Cohen, Irit Avivi Mazza, Cyrille Cohen, Moshe E. Gatt, Polina Stepensky

Bar-Ilan University

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

Cohen: Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Avivi Mazza: AbbVie: Honoraria.

Original language	English
Number of pages	4
Journal	Blood
Volume	142
State	Published - 2 Nov 2023

Cite this

Lebel, E., Asherie, N., Kfir-Erenfeld, S., Batia, A., Grisariu, S., Elias, S., Assayag, M., Dubnikov, T., Zalcman, N., Pick, M., Zimran, E., Cohen, Y. C., Mazza, I. A., Cohen, C., Gatt, M. E., & Stepensky, P. (2023). Safety and Efficacy of a Locally Produced Novel Anti- BCMA Chimeric Antigen Receptor TCell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma. Blood, 142.

@article{d767dacd1464433e85bcecd7f0ffbcd5,

title = "Safety and Efficacy of a Locally Produced Novel Anti- BCMA Chimeric Antigen Receptor TCell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma",

abstract = "Cohen: Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Avivi Mazza: AbbVie: Honoraria.",

author = "Eyal Lebel and Nathalie Asherie and Shlomit Kfir-Erenfeld and Avni Batia and Sigal Grisariu and Shlomo Elias and Miri Assayag and Tatyana Dubnikov and Nomi Zalcman and Marjorie Pick and Eran Zimran and Cohen, {Yael C.} and Mazza, {Irit Avivi} and Cyrille Cohen and Gatt, {Moshe E.} and Polina Stepensky",

year = "2023",

month = nov,

day = "2",

language = "الإنجليزيّة",

volume = "142",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier BV",

}

Lebel, E, Asherie, N, Kfir-Erenfeld, S, Batia, A, Grisariu, S, Elias, S, Assayag, M, Dubnikov, T, Zalcman, N, Pick, M, Zimran, E, Cohen, YC, Mazza, IA, Cohen, C, Gatt, ME & Stepensky, P 2023, 'Safety and Efficacy of a Locally Produced Novel Anti- BCMA Chimeric Antigen Receptor TCell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma', Blood, vol. 142.

TY - JOUR

T1 - Safety and Efficacy of a Locally Produced Novel Anti- BCMA Chimeric Antigen Receptor TCell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma

AU - Lebel, Eyal

AU - Asherie, Nathalie

AU - Kfir-Erenfeld, Shlomit

AU - Batia, Avni

AU - Grisariu, Sigal

AU - Elias, Shlomo

AU - Assayag, Miri

AU - Dubnikov, Tatyana

AU - Zalcman, Nomi

AU - Pick, Marjorie

AU - Zimran, Eran

AU - Cohen, Yael C.

AU - Mazza, Irit Avivi

AU - Cohen, Cyrille

AU - Gatt, Moshe E.

AU - Stepensky, Polina

PY - 2023/11/2

Y1 - 2023/11/2

N2 - Cohen: Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Avivi Mazza: AbbVie: Honoraria.

AB - Cohen: Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Avivi Mazza: AbbVie: Honoraria.

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=barilanwos&SrcAuth=WosAPI&KeyUT=WOS:001159900800053&DestLinkType=FullRecord&DestApp=WOS_CPL

M3 - موجز برنامج المؤتمر

SN - 0006-4971

VL - 142

JO - Blood

JF - Blood

ER -

Safety and Efficacy of a Locally Produced Novel Anti- BCMA Chimeric Antigen Receptor TCell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma

Abstract

Other files and links

Cite this